Combined blood markers correctly detect early pancreatic cancer in human cancer cells
A newly identified biomarker panel could pave the way to earlier detection and better treatment for pancreatic cancer, according to new research from the Perelman School of Medicine at University of Pennsylvania. Currently over 53,000 people in the United States are diagnosed with pancreatic cancer — the fourth leading cause of cancer death — every year. The blood biomarkers, detailed today in Science Translational Medicine, correctly detected pancreatic cancer in blood samples from patients at different stages of their disease.
The majority of pancreatic cancer patients are not diagnosed until an advanced stage, beyond the point at which their tumors can be surgically removed.
A team led by Ken Zaret, PhD, director of the Penn Institute for Regenerative Medicine and the Joseph Leidy Professor of Cell and Developmental Biology, and Gloria Petersen, PhD, from the Mayo Clinic, identified a pair of biomarkers that physicians could soon use to discover the disease earlier.
“Starting with our cell model that mimics human pancreatic cancer progression, we identified released proteins, then tested and validated a subset of these proteins as potential plasma biomarkers of this cancer,” Zaret said. The authors anticipate that health care providers will use the early-detection biomarkers to test for their presence and levels in blood from pancreatic cancer patients and blood drawn from individuals with a high risk of developing pancreatic cancer, including those who have a first-degree relative with pancreatic cancer, are genetically predisposed to the disease, or who had a sudden onset of diabetes after the age of 50.
“Early detection of cancer has had a critical influence on lessening the impact of many types of cancer, including breast, colon, and cervical cancer. A long standing concern has been that patients with pancreatic cancer are often not diagnosed until it is too late for the best chance at effective treatment,” said Robert Vonderheide, MD, DPhil, director of the Abramson Cancer Center (ACC) at the University of Pennsylvania. “Having a biomarker test for this disease could dramatically alter the outlook for these patients.”
Novel method for discovering pancreatic cancer biomarkers
Credit: The lab of Ken Zaret, Perelman School of Medicine, University of Pennsylvania
The biomarker panel, enabled by discovery work of first author Jungsun Kim, PhD, a postdoctoral fellow in Zaret’s lab, builds on a first-of-its-kind human-cell model of pancreatic cancer progression the lab described in 2013. They used stem-cell technology to create a cell line from a patient with advanced pancreatic ductal adenocarcinoma. Genetically reprogramming late-stage human cancer cells to a stem-cell state enabled them to force the reprogrammed cells to progress to an early cancerous state, revealing secreted blood biomarkers of early-stage disease along the way.
The best candidate biomarker, plasma thrombospondin-2 (THBS2), was screened against 746 cancer and control plasma samples using an inexpensive, commercially available protein-detection assay. The team found that blood levels of THBS2, combined with levels of a known later-stage biomarker called CA19-9, was reliable at detecting the presence of pancreatic cancer in patients.
The team refined the assay with independent investigations of plasma samples from patients with different stages of cancer, from individuals with benign pancreatic disease, and from healthy controls, all obtained from Petersen, who directs the biospecimen resource program for pancreas research at the Mayo Clinic.
“Positive results for THBS2 or CA19-9 concentrations in the blood consistently and correctly identified all stages of the cancer,” Zaret said. “Notably, THBS2 concentrations combined with CA19-9 identified early stages better than any other known method.” The combination panel also improved the ability to distinguish cases of cancer from pancreatitis. The panel will next be validated in a set of samples from pancreatic cancer patients who provided a research blood sample prior to their diagnosis.
The Latest on: Pancreatic cancer
- Former Sen. Harry Reid Says He's in 'Complete Remission' After Pancreatic Cancer Treatmenton June 25, 2020 at 8:37 am
Former Sen. Harry Reid tells PEOPLE that he's in "complete remission" from pancreatic cancer after undergoing an experimental therapy treatment created by Dr. Patrick Soon-Shiong ...
- Global Pancreatic Cancer Clinical Trial Pipeline Highlights 2020 - ResearchAndMarkets.comon June 25, 2020 at 6:15 am
The "Global Pancreatic Cancer Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.
- The miR-92a-2-5p in exosomes from macrophages increases liver cancer cells invasion via altering the AR/PHLPP/p-AKT/β-catenin signalingon June 25, 2020 at 12:17 am
Early studies indicated that the androgen receptor (AR) might play important roles in the regulating of the initiation and progression of hepatocellular carcinoma (HCC), but its linkage to the ...
- For 16th Consecutive Year, Pancreatic Cancer Action Network Awarded Four-Star Rating From Charity Navigatoron June 24, 2020 at 5:26 am
For 16th Consecutive Year, Pancreatic Cancer Action Network Awarded Four-Star Rating From Charity NavigatorPR NewswireMANHATTAN BEACH, Calif., June 24, 2020Fewer Than One Percent of All Rated ...
- PharmaCyte Biotech Provides IND Submission Update for Pancreatic Cancer Clinical Trialon June 23, 2020 at 4:00 am
Set forth below is a list of the major items to be finalized by PharmaCyte and its consultants before PharmaCyte submits the IND to the FDA. Study Reports and related information of prior clinical ...
- Couple's Engagement Encourages Single Mother Battling Pancreatic Canceron June 22, 2020 at 5:06 pm
COVID-19 concerns couldn’t keep a local couple from starting a new chapter this weekend, and their socially-distanced engagement celebration may have meant even more to one Minnesota mother, Frank ...
- AACR: Attacking pancreatic cancer by thwarting its survival strategieson June 22, 2020 at 6:35 am
At this week’s virtual meeting of the American Association for Cancer Research (AACR), several research groups are presenting new therapeutic tactics aimed at interrupting survival pathways in ...
- 4 Things About Pancreatic Cancer Diagnostic Market That Will Change Coming Decadeon June 19, 2020 at 10:26 am
Click to get Global Pancreatic Cancer Diagnostic Market Research Sample PDF Copy Here @ According to the American Cancer Society, around 3 percent of all cancers in the United States are pancreatic ...
- Pancreatic Cancer Therapeutics Market 2020 Analysis report with Cross-Channel, Opportunities, Upturn Growth by 2026on June 19, 2020 at 3:51 am
The report provides rational insights along with historical and forecast data to aid in better understanding of ...
- 5 for Good: Local families advocate for support in fighting pancreatic canceron June 18, 2020 at 8:35 pm
To recognize it early, because that can really make a difference in the survival rate." Improved in recent years, the survival rate for pancreatic cancer patients is still very low. According to the ...
via Google News and Bing News